Statement on President Trump’s State of the Union Remarks on Ending the U.S. HIV Epidemic by 2030 from the Act Now: End AIDS Coalition
This statement was released last night by ANEA in response to the President’s SOTU announcement.
Public Comment on NIDA Strategic Plan for Research at the Intersection of HIV/AIDS and Substance Use, Misuse, and Addiction
TAG recently submitted a public comment to the National Institute on Drug Abuse (NIDA) at the National Institute of Health to inform a strategic plan it is developing to support research at the intersection of HIV and drug use.
Cutting Costs by Including Cheaper ARVs on the New York State Medicaid Preferred Drug List for treatment, PEP, and potentially PrEP
On January 17, 2019, Treatment Action Group and Housing Works presented this webinar discussing current advocacy to cut costs by scaling up the use of Mylan’s Cimduo (TDF/3TC) and Symfi (EFV/TDF/3TC) as part of New York State Medicaid. Tim Horn…
Public Comment on USPSTF Draft Recommendations for PrEP and HIV Screening
The US Preventive Services Task Force (USPSTF) recently released draft recommendations regarding HIV screening for all Americans ages 15-65, including pregnant women, and pre-exposure prophylaxis (PrEP) for individuals highly vulnerable to HIV infection.
Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing
By Bryn Gay, HCV Project Director, TAG and Claudine Guerra, CUNY DOWNLOAD to print this article as a poster (A1 size) The current leaders of the United States manufacture crises, media optics, and catchy sound bites to side step actual…
Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research
By Richard Jefferys, Basic Science, Vaccines, and Cure Project Director, TAG The history of antiretroviral (ARV) drug development offers many examples of compounds that were originally discovered and investigated by publicly funded academic researchers, before being acquired and ushered to…
Getting Rid of the Boogeyman: The Reality of Prescription Drug Price Controls
By Annette Gaudino, HCV/HIV Project Co-Director, TAG Do you remember how old you were when you stopped believing in the monster under your bed? How many times did you have to look and see nothing there before you finally believed…
Fierce Activism from the Global Access to Medicines (A2M) Movement: Reflections on Recent Sucess
By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …
Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards
By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American…
Treatment Action Group Generates Novel HIV Cure Research Resources with the Support of the Elizabeth Taylor AIDS Foundation and Macy’s Inc./“Thanks for Giving”
Treatment Action Group has released a new report focusing on the ethically complex and potentially risky aspect of research aiming to develop a cure for HIV infection: the use of “analytical treatment interruptions” (ATIs) in clinical studies to investigate how HIV viral load rebounds, and whether experimental interventions can limit viral replication after antiretroviral therapy (ART) is interrupted.